165 related articles for article (PubMed ID: 36166107)
21. Review and Update of the Risk Factors and Prevention of Antiresorptive-Related Osteonecrosis of the Jaw.
Kim HY
Endocrinol Metab (Seoul); 2021 Oct; 36(5):917-927. PubMed ID: 34674506
[TBL] [Abstract][Full Text] [Related]
22. Major histocompatibility complex class II polymorphisms are associated with the development of anti-resorptive agent-induced osteonecrosis of the jaw.
Stockmann P; Nkenke E; Englbrecht M; Schlittenbauer T; Wehrhan F; Rauh C; Beckmann MW; Fasching PA; Kreusch T; Mackensen A; Wullich B; Schett G; Spriewald BM
J Craniomaxillofac Surg; 2013 Jan; 41(1):71-5. PubMed ID: 23218978
[TBL] [Abstract][Full Text] [Related]
23. Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study.
Ristow O; Rückschloß T; Müller M; Berger M; Kargus S; Pautke C; Engel M; Hoffmann J; Freudlsperger C
J Craniomaxillofac Surg; 2019 Mar; 47(3):491-499. PubMed ID: 30642734
[TBL] [Abstract][Full Text] [Related]
24. Continuous Mandibular Nerve Block for Intractable Mandibular Pain Due to Antiresorptive Agent-Related Osteonecrosis of the Jaw: A Case Report.
Fujimoto D; Obata N; Motoyama Y; Sato H; Takao Y; Mizobuchi S
Kobe J Med Sci; 2020 Nov; 66(3):E90-E93. PubMed ID: 33431781
[TBL] [Abstract][Full Text] [Related]
25. Antiresorptive drug-related osteonecrosis of the jaws, literature review and 5 years of experience.
Bernardi S; Di Girolamo M; Necozione S; Continenza MA; Cutilli T
Musculoskelet Surg; 2019 Apr; 103(1):47-53. PubMed ID: 29948937
[TBL] [Abstract][Full Text] [Related]
26. Issues with the surgical treatment of antiresorptive agent-related osteonecrosis of the jaws.
Kagami H; Inoue M; Kobayashi A; Taguchi A; Li X; Yoshizawa M
Oral Dis; 2018 Mar; 24(1-2):52-56. PubMed ID: 29480637
[TBL] [Abstract][Full Text] [Related]
27. Incidence of antiresorptive agent-related osteonecrosis of the jaw: A multicenter retrospective epidemiological study in Hyogo Prefecture, Japan.
Nashi M; Kishimoto H; Kobayashi M; Tachibana A; Suematsu M; Fujiwara S; Ota Y; Hashitani S; Shibatsuji T; Nishida T; Fujimura K; Furudoi S; Ishida Y; Ishii S; Fujita T; Iwai S; Shigeta T; Harada T; Miyai D; Takeda D; Akashi M; Noguchi K; Takenobu T
J Dent Sci; 2023 Jul; 18(3):1156-1163. PubMed ID: 37404599
[TBL] [Abstract][Full Text] [Related]
28. Bone scan index of the jaw: a new approach for evaluating early-stage anti-resorptive agents-related osteonecrosis.
Watanabe S; Nakajima K; Mizokami A; Yaegashi H; Noguchi N; Kawashiri S; Inokuchi M; Kinuya S
Ann Nucl Med; 2017 Apr; 31(3):201-210. PubMed ID: 27995542
[TBL] [Abstract][Full Text] [Related]
29. Effect of morphological findings in computed tomography on the quantitative values in single-photon emission computed tomography for patients with antiresorptive agent-related osteonecrosis of the jaw: a cross-sectional study.
Kobayashi Y; Okui T; Tsujimoto M; Ikeda H; Satoh K; Kanamori D; Fujii N; Toyama H; Matsuo K
Ann Nucl Med; 2021 Jul; 35(7):853-860. PubMed ID: 33997910
[TBL] [Abstract][Full Text] [Related]
30. Antiresorptive agents-related osteonecrosis of the jaw (ARONJ) in rheumatoid arthritis.
Fujieda Y; Atsumi T
J Bone Miner Metab; 2020 Sep; 38(5):739-741. PubMed ID: 32591907
[No Abstract] [Full Text] [Related]
31. [A Case Report of Kampo Medicine Improving the Symptoms of Antiresorptive Agent-related Osteonecrosis of the Jaw (ARONJ)].
Yamazaki Y; Shimada M
Yakugaku Zasshi; 2021; 141(9):1123-1127. PubMed ID: 34471013
[TBL] [Abstract][Full Text] [Related]
32. Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?
Sidhu HK
Dent Update; 2015 Jun; 42(5):436-8, 440. PubMed ID: 26964445
[TBL] [Abstract][Full Text] [Related]
33. Synchronous antiresorptive osteonecrosis of the jaws and breast cancer metastasis.
Flores IL; dos Santos-Silva AR; Della Coletta R; Vargas PA; Lopes MA
Oral Surg Oral Med Oral Pathol Oral Radiol; 2014 Mar; 117(3):e264-8. PubMed ID: 24528798
[TBL] [Abstract][Full Text] [Related]
34. Predictive factors for refractory stage I and II anti-resorptive agent-related osteonecrosis of the jaw.
Shimizu T; Kim M; Dam TT; Kurihara J; Ogawa M; Makiguchi T; Yokoo S
Oral Radiol; 2022 Apr; 38(2):240-251. PubMed ID: 34218422
[TBL] [Abstract][Full Text] [Related]
35. Antiresorptive agent-related osteonecrosis of the jaw in osteoporosis patients from Asian countries.
Taguchi A; Shiraki M; Morrison A; Khan AA
Osteoporos Sarcopenia; 2017 Jun; 3(2):64-74. PubMed ID: 30775507
[TBL] [Abstract][Full Text] [Related]
36. [Use of a xenogeneic collagen matrix on extraction sockets: a new approach in ARONJ prevention (in german)].
Kuster I; Valdec S; Rücker M; Bichsel D
Swiss Dent J; 2020 Feb; 130(2):139-145. PubMed ID: 32031353
[TBL] [Abstract][Full Text] [Related]
37. Quantitative bone scan imaging using BSI and BUV: an approach to evaluate ARONJ early.
Yamamoto Y; Mitsunaga S; Horikawa A; Hino A; Kurihara H
Ann Nucl Med; 2020 Jan; 34(1):74-79. PubMed ID: 31705367
[TBL] [Abstract][Full Text] [Related]
38. Interventions for managing medication-related osteonecrosis of the jaw.
Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012432. PubMed ID: 28983908
[TBL] [Abstract][Full Text] [Related]
39. Emerging therapies with potential risks of medicine-related osteonecrosis of the jaw: a review of the literature.
Kanwar N; Bakr MM; Meer M; Siddiqi A
Br Dent J; 2020 Jun; 228(11):886-892. PubMed ID: 32541753
[TBL] [Abstract][Full Text] [Related]
40. Odontogenic infection and antiresorptive agent-related osteonecrosis of the jaw with facial subcutaneous abscess formation: A retrospective clinical study of difficult-to-diagnose cases.
Matsumoto Y; Yokoi H; Ikeda T; Kawada M; Ogawa M; Saito K
Auris Nasus Larynx; 2021 Aug; 48(4):758-763. PubMed ID: 33436301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
